JP5632581B2 - 結腸直腸癌の予後予測 - Google Patents
結腸直腸癌の予後予測 Download PDFInfo
- Publication number
- JP5632581B2 JP5632581B2 JP2008547140A JP2008547140A JP5632581B2 JP 5632581 B2 JP5632581 B2 JP 5632581B2 JP 2008547140 A JP2008547140 A JP 2008547140A JP 2008547140 A JP2008547140 A JP 2008547140A JP 5632581 B2 JP5632581 B2 JP 5632581B2
- Authority
- JP
- Japan
- Prior art keywords
- expression
- gene
- data
- prognostic
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010009944 Colon cancer Diseases 0.000 title claims description 55
- 238000004393 prognosis Methods 0.000 title claims description 49
- 208000001333 Colorectal Neoplasms Diseases 0.000 title description 61
- 108091034117 Oligonucleotide Proteins 0.000 claims description 17
- 239000000758 substrate Substances 0.000 claims description 10
- 230000002068 genetic effect Effects 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 description 140
- 206010028980 Neoplasm Diseases 0.000 description 129
- 230000014509 gene expression Effects 0.000 description 117
- 239000000523 sample Substances 0.000 description 117
- 238000000034 method Methods 0.000 description 111
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 53
- 201000011510 cancer Diseases 0.000 description 51
- 230000000306 recurrent effect Effects 0.000 description 42
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 239000003550 marker Substances 0.000 description 29
- 201000010099 disease Diseases 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 26
- 239000013615 primer Substances 0.000 description 26
- 238000002493 microarray Methods 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 25
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 238000002790 cross-validation Methods 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 22
- 230000004083 survival effect Effects 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 238000010606 normalization Methods 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 108091033319 polynucleotide Proteins 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 238000013459 approach Methods 0.000 description 17
- 238000007418 data mining Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 239000002157 polynucleotide Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 238000009396 hybridization Methods 0.000 description 14
- 230000035945 sensitivity Effects 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 238000003753 real-time PCR Methods 0.000 description 13
- 238000003757 reverse transcription PCR Methods 0.000 description 13
- 238000012706 support-vector machine Methods 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 12
- 238000012549 training Methods 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 238000012795 verification Methods 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000013461 design Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000002987 primer (paints) Substances 0.000 description 9
- 238000010200 validation analysis Methods 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 108010012236 Chemokines Proteins 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000012775 microarray technology Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000013610 patient sample Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 206010038111 Recurrent cancer Diseases 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 230000004547 gene signature Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 238000013528 artificial neural network Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 238000010208 microarray analysis Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000012353 t test Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 101000762967 Homo sapiens Lymphokine-activated killer T-cell-originated protein kinase Proteins 0.000 description 4
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 4
- 102100026753 Lymphokine-activated killer T-cell-originated protein kinase Human genes 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- -1 large intestine) Diseases 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 101150092328 22 gene Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 206010061819 Disease recurrence Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 3
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 3
- 208000037062 Polyps Diseases 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000011223 gene expression profiling Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000010801 machine learning Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 101150040471 19 gene Proteins 0.000 description 2
- 102100024642 ATP-binding cassette sub-family C member 9 Human genes 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 2
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102100035099 General transcription factor 3C polypeptide 5 Human genes 0.000 description 2
- 102100030385 Granzyme B Human genes 0.000 description 2
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 2
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 description 2
- 101000760581 Homo sapiens ATP-binding cassette sub-family C member 9 Proteins 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 2
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 2
- 101000596761 Homo sapiens General transcription factor 3C polypeptide 5 Proteins 0.000 description 2
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 2
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 2
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 2
- 101001001336 Homo sapiens Guanylate-binding protein 1 Proteins 0.000 description 2
- 101001081176 Homo sapiens Hyaluronan mediated motility receptor Proteins 0.000 description 2
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 2
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 2
- 101000711744 Homo sapiens Non-secretory ribonuclease Proteins 0.000 description 2
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 2
- 101000893674 Homo sapiens Ras GTPase-activating protein-binding protein 2 Proteins 0.000 description 2
- 101000761737 Homo sapiens Ubiquitin-conjugating enzyme E2 L3 Proteins 0.000 description 2
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 102100034217 Non-secretory ribonuclease Human genes 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 102100040857 Ras GTPase-activating protein-binding protein 2 Human genes 0.000 description 2
- 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102100028787 Tumor necrosis factor receptor superfamily member 11A Human genes 0.000 description 2
- 102100024861 Ubiquitin-conjugating enzyme E2 L3 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 238000013473 artificial intelligence Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000003046 intermediate neglect of differential overlap Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000575 proteomic method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000009540 villous adenoma Diseases 0.000 description 2
- 102100036659 26S proteasome non-ATPase regulatory subunit 9 Human genes 0.000 description 1
- 102100022644 26S proteasome regulatory subunit 4 Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091029845 Aminoallyl nucleotide Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100024311 COMM domain-containing protein 2 Human genes 0.000 description 1
- 102100039534 Calcium-activated chloride channel regulator 4 Human genes 0.000 description 1
- 102100029184 Calmodulin regulator protein PCP4 Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100037980 Disks large-associated protein 5 Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010089790 Eukaryotic Initiation Factor-3 Proteins 0.000 description 1
- 102100029776 Eukaryotic translation initiation factor 3 subunit D Human genes 0.000 description 1
- 102100023236 Eukaryotic translation initiation factor 3 subunit G Human genes 0.000 description 1
- 208000010368 Extramammary Paget Disease Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000000321 Gardner Syndrome Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 101001136710 Homo sapiens 26S proteasome non-ATPase regulatory subunit 9 Proteins 0.000 description 1
- 101000619137 Homo sapiens 26S proteasome regulatory subunit 4 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000909581 Homo sapiens COMM domain-containing protein 2 Proteins 0.000 description 1
- 101000888577 Homo sapiens Calcium-activated chloride channel regulator 4 Proteins 0.000 description 1
- 101000988362 Homo sapiens Calmodulin regulator protein PCP4 Proteins 0.000 description 1
- 101000951365 Homo sapiens Disks large-associated protein 5 Proteins 0.000 description 1
- 101001012766 Homo sapiens Eukaryotic translation initiation factor 3 subunit D Proteins 0.000 description 1
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 1
- 101000957259 Homo sapiens Mitotic spindle assembly checkpoint protein MAD2A Proteins 0.000 description 1
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 description 1
- 101000869517 Homo sapiens Phosphatidylinositol-3-phosphatase SAC1 Proteins 0.000 description 1
- 101000615933 Homo sapiens Phosphoserine aminotransferase Proteins 0.000 description 1
- 101000919980 Homo sapiens Protoheme IX farnesyltransferase, mitochondrial Proteins 0.000 description 1
- 101000637839 Homo sapiens Serine/threonine-protein kinase tousled-like 1 Proteins 0.000 description 1
- 101000802948 Homo sapiens Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform Proteins 0.000 description 1
- 101001093181 Homo sapiens Short coiled-coil protein Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 101000955100 Homo sapiens WD repeat-containing protein 44 Proteins 0.000 description 1
- 101000818532 Homo sapiens Zinc finger and BTB domain-containing protein 20 Proteins 0.000 description 1
- 101000976610 Homo sapiens Zinc finger protein 410 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100038792 Mitotic spindle assembly checkpoint protein MAD2A Human genes 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100028467 Perforin-1 Human genes 0.000 description 1
- 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 1
- 102100032286 Phosphatidylinositol-3-phosphatase SAC1 Human genes 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100030729 Protoheme IX farnesyltransferase, mitochondrial Human genes 0.000 description 1
- 206010056626 Pseudopolyp Diseases 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108091006262 SLC4A4 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100032015 Serine/threonine-protein kinase tousled-like 1 Human genes 0.000 description 1
- 102100035728 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform Human genes 0.000 description 1
- 102100036292 Short coiled-coil protein Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102000006633 Sodium-Bicarbonate Symporters Human genes 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100038961 WD repeat-containing protein 44 Human genes 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 102100021146 Zinc finger and BTB domain-containing protein 20 Human genes 0.000 description 1
- 102100023547 Zinc finger protein 410 Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 208000017563 cutaneous Paget disease Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 238000007636 ensemble learning method Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- QPMJENKZJUFOON-PLNGDYQASA-N ethyl (z)-3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/Cl)C(F)(F)F QPMJENKZJUFOON-PLNGDYQASA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000012880 independent component analysis Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000020123 juvenile polyp Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000010148 papillary adenoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/30—Microarray design
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ544432 | 2005-12-23 | ||
| NZ544432A NZ544432A (en) | 2005-12-23 | 2005-12-23 | Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS |
| PCT/NZ2006/000343 WO2007073220A1 (en) | 2005-12-23 | 2006-12-22 | Prognosis prediction for colorectal cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014103714A Division JP6218141B2 (ja) | 2005-12-23 | 2014-05-19 | 結腸直腸癌の予後予測 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009521215A JP2009521215A (ja) | 2009-06-04 |
| JP2009521215A5 JP2009521215A5 (enExample) | 2013-01-10 |
| JP5632581B2 true JP5632581B2 (ja) | 2014-11-26 |
Family
ID=38188869
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008547140A Expired - Fee Related JP5632581B2 (ja) | 2005-12-23 | 2006-12-22 | 結腸直腸癌の予後予測 |
| JP2014103714A Expired - Fee Related JP6218141B2 (ja) | 2005-12-23 | 2014-05-19 | 結腸直腸癌の予後予測 |
| JP2015257292A Expired - Fee Related JP6058780B2 (ja) | 2005-12-23 | 2015-12-28 | 結腸直腸癌の予後予測 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014103714A Expired - Fee Related JP6218141B2 (ja) | 2005-12-23 | 2014-05-19 | 結腸直腸癌の予後予測 |
| JP2015257292A Expired - Fee Related JP6058780B2 (ja) | 2005-12-23 | 2015-12-28 | 結腸直腸癌の予後予測 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10422005B2 (enExample) |
| EP (3) | EP2371972B1 (enExample) |
| JP (3) | JP5632581B2 (enExample) |
| KR (3) | KR101530689B1 (enExample) |
| CN (1) | CN101389957B (enExample) |
| AU (1) | AU2006328023B2 (enExample) |
| CA (2) | CA3015335A1 (enExample) |
| ES (3) | ES2525219T3 (enExample) |
| NZ (3) | NZ544432A (enExample) |
| WO (1) | WO2007073220A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2783348B1 (fr) * | 1998-09-15 | 2000-10-13 | Alstom Technology | Methode de discrimination entre un arc interne et un arc de coupure dans un disjoncteur de moyenne ou de haute tension |
| EP2947160B1 (en) | 2004-04-09 | 2017-07-12 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| NZ593226A (en) | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (efnb2) for colorectal cancer prognosis |
| ES2599816T3 (es) * | 2006-07-21 | 2017-02-03 | Epigenomics Ag | Métodos relacionados con el gen GLI3 para la detección de cáncer colorrectal |
| DE102006035393A1 (de) * | 2006-11-02 | 2008-05-15 | Signature Diagnostics Ag | Prognostische Marker für die Klassifizierung des dreijährigen progessionsfreien Überlebens von Patienten mit Kolonkarzinomen basierend auf Expressionsprofilen von biologischen Proben |
| US20090076734A1 (en) | 2007-03-22 | 2009-03-19 | Torres-Roca Javier F | Gene Signature for the Prediction of Radiation Therapy Response |
| US20080234946A1 (en) * | 2007-03-22 | 2008-09-25 | University Of South Florida | Predictive radiosensitivity network model |
| EP2544006A1 (en) * | 2007-06-04 | 2013-01-09 | Diagnoplex | Biomarker combinations for colorectal cancer |
| NZ562237A (en) * | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| ES2332557B1 (es) | 2007-12-04 | 2011-02-02 | Universidad Autonoma De Madrid | Huella genomica para el pronostico de la evolucion de adenocarcinoma colorectal. |
| CN104376147B (zh) * | 2009-02-02 | 2018-07-17 | 罗格斯新泽西州立大学 | 基于图像的风险分数的图像分析系统 |
| NZ596054A (en) | 2009-05-01 | 2013-07-26 | Genomic Health Inc | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy |
| EP2454596B1 (en) | 2009-07-16 | 2014-06-11 | Roche Diagnostics GmbH | Flap endonuclease-1 as a marker for cancer |
| US8445271B2 (en) | 2010-05-03 | 2013-05-21 | Enzo Life Sciences, Inc. | Processes and kits for determining multi-drug resistance of cells |
| WO2011140662A1 (en) * | 2010-05-13 | 2011-11-17 | The Royal Institution For The Advancement Of Learning / Mcgill University | Cux1 signature for determination of cancer clinical outcome |
| JP5916718B2 (ja) * | 2010-06-04 | 2016-05-11 | ビオメリューBiomerieux | 結腸直腸癌の予後判定のための方法及びキット |
| US9539323B2 (en) | 2010-08-06 | 2017-01-10 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy |
| KR101401561B1 (ko) * | 2010-12-30 | 2014-06-11 | 주식회사 바이오인프라 | 복합 바이오마커를 활용한 암 진단 정보 생성 방법, 및 암 진단 예측 시스템 장치 |
| US20120184454A1 (en) * | 2011-01-14 | 2012-07-19 | Kalady Matthew F | Gene signature is associated with early stage rectal cancer recurrence |
| CN102183662A (zh) * | 2011-03-22 | 2011-09-14 | 浙江大学 | 一种大肠癌预后预测模型的建立方法 |
| CA2857073A1 (en) * | 2011-11-28 | 2013-06-06 | Institucio Catalana De Recerca I Estudis Avancats | Methods and kits for the prognosis of colorectal cancer |
| US9977033B2 (en) * | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
| KR20160045547A (ko) | 2014-10-17 | 2016-04-27 | 에스케이텔레콤 주식회사 | 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법 |
| CN105021828B (zh) * | 2015-07-20 | 2017-07-28 | 上海交通大学医学院附属新华医院 | 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后 |
| SG11201806609TA (en) | 2016-02-02 | 2018-09-27 | Guardant Health Inc | Cancer evolution detection and diagnostic |
| WO2017143322A1 (en) | 2016-02-18 | 2017-08-24 | University Of South Florida | Materials and methods for detecting cancer based on urinary levels of rhamm |
| US20190242875A1 (en) | 2016-05-10 | 2019-08-08 | National University Corporation Tokyo Medical And Dental University | Expression Inhibitor of Inflammation Promoting Factor, Screening Method for Active Ingredient Thereof, Expression Cassette Useful for Said Method, Diagnostic Agent and Diagnosis Method |
| US11164082B2 (en) | 2017-02-28 | 2021-11-02 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| US9934364B1 (en) | 2017-02-28 | 2018-04-03 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| US10360499B2 (en) * | 2017-02-28 | 2019-07-23 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| WO2018231772A1 (en) | 2017-06-13 | 2018-12-20 | Bostongene Corporation | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy |
| EP3719124A4 (en) | 2017-11-09 | 2021-09-01 | National University Corporation Tokyo Medical and Dental University | CANCER-PROMOTING EXPRESSION INHIBITOR, SCREENING METHOD FOR ACTIVE SUBSTANCE, USEFUL EXPRESSION CASSETTE IN SUCH METHOD, DIAGNOSIS DRUG AND DIAGNOSIS METHOD |
| WO2019154884A1 (en) * | 2018-02-07 | 2019-08-15 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for determining cancer invasiveness and patient prognosis |
| WO2019173233A1 (en) * | 2018-03-05 | 2019-09-12 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| TW202018727A (zh) | 2018-11-09 | 2020-05-16 | 財團法人工業技術研究院 | 整體式學習預測方法與系統 |
| CN111321221B (zh) * | 2018-12-14 | 2022-09-23 | 中国医学科学院肿瘤医院 | 用于预测直肠癌局部切除手术后复发风险的组合物、微阵列和计算机系统 |
| CN109599181B (zh) * | 2019-01-09 | 2021-04-16 | 中国医学科学院肿瘤医院 | 一种在治疗前针对t3-larc患者的生存预测系统及预测方法 |
| CA3128973A1 (en) | 2019-03-04 | 2020-09-10 | Bhaskar Bhattacharyya | Data compression and communication using machine learning |
| CN109811057B (zh) * | 2019-03-27 | 2022-02-22 | 中山大学附属第六医院 | 缺氧相关基因在结直肠癌预测系统中的应用 |
| CN109762907B (zh) * | 2019-03-27 | 2022-02-22 | 中山大学附属第六医院 | 缺氧相关基因在预测i/ii期结直肠癌的试剂盒中的应用 |
| US11154240B2 (en) | 2019-04-02 | 2021-10-26 | Kpn Innovations Llc | Methods and systems for utilizing diagnostics for informed vibrant constitutional guidance |
| CN110246591B (zh) * | 2019-07-15 | 2021-11-05 | 中国中医科学院西苑医院 | 一种中医药治疗人群的预后预测系统 |
| CN112342295A (zh) * | 2019-08-06 | 2021-02-09 | 中山大学孙逸仙纪念医院 | 一种检测人结直肠癌的肿瘤标志物及其应用 |
| CN110791565B (zh) * | 2019-09-29 | 2021-09-03 | 浙江大学 | 一种用于ii期结直肠癌复发预测的预后标记基因及随机生存森林模型 |
| WO2021119761A1 (en) | 2019-12-20 | 2021-06-24 | Hudson Institute of Medical Research | Cxcl10 binding proteins and uses thereof |
| US12020417B2 (en) * | 2020-04-24 | 2024-06-25 | Camtek Ltd. | Method and system for classifying defects in wafer using wafer-defect images, based on deep learning |
| US11289206B2 (en) | 2020-06-02 | 2022-03-29 | Kpn Innovations, Llc. | Artificial intelligence methods and systems for constitutional analysis using objective functions |
| US12176108B2 (en) | 2020-06-02 | 2024-12-24 | Kpn Innovations Llc | Artificial intelligence methods and systems for constitutional analysis using objective functions |
| US11211158B1 (en) | 2020-08-31 | 2021-12-28 | Kpn Innovations, Llc. | System and method for representing an arranged list of provider aliment possibilities |
| CN112301131B (zh) * | 2020-11-13 | 2021-10-26 | 中国医学科学院基础医学研究所 | Rnf138作为预测结直肠癌对sc75741治疗敏感性的生物标志物的应用 |
| CN113591919B (zh) * | 2021-06-29 | 2023-07-21 | 复旦大学附属中山医院 | 基于ai对早期肝细胞癌术后复发预后的分析方法及系统 |
| WO2023128419A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 이노제닉스 | 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용 |
| IT202200001817A1 (it) | 2022-02-02 | 2023-08-02 | Aizoon S R L | Procedimento per la prognosi di una malattia in seguito ad un trattamento terapeutico, relativo sistema e prodotto informatico |
| CN114652814B (zh) * | 2022-03-11 | 2023-02-03 | 郑州大学第一附属医院 | 一种免疫检查点抑制剂及应用 |
| IT202200005861A1 (it) | 2022-03-24 | 2023-09-24 | Aizoon S R L | Procedimento per stimare una variabile di interesse associata ad una data malattia in funzione di una pluralità di diversi dati omici, relativo dispositivo e prodotto informatico |
| CA3207405A1 (en) | 2022-07-25 | 2024-01-25 | Aizoon S.r.l. | Method for providing a clinical decision support, corresponding system for providing a clinical decision support, and computer program product |
| WO2024138106A1 (en) * | 2022-12-23 | 2024-06-27 | The Wistar Institute Of Anatomy And Biology | Compositions and methods for identification of hypomorphic p53 variants |
| CN115938590B (zh) * | 2023-02-09 | 2023-05-02 | 四川大学华西医院 | 结直肠癌术后lars预测模型的构建方法及预测系统 |
| CN117947166B (zh) * | 2024-01-30 | 2025-08-29 | 复旦大学附属肿瘤医院 | 用于肠癌预后的标志物组、产品、系统及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| GB9805918D0 (en) * | 1998-03-19 | 1998-05-13 | Nycomed Amersham Plc | Sequencing by hybridisation |
| JP2004510951A (ja) * | 1999-03-15 | 2004-04-08 | イオス バイオテクノロジー,インコーポレイティド | 結腸直腸癌を診断する新規の方法、組成物、結腸直腸癌調節のためのスクリーニング法 |
| WO2002006867A2 (en) | 2000-07-18 | 2002-01-24 | Kvh Industries, Inc. | Method of incorporating optical material into an optical fiber |
| US20030077568A1 (en) * | 2000-09-15 | 2003-04-24 | Gish Kurt C. | Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| AU2002252144A1 (en) * | 2001-02-27 | 2002-09-12 | Case Western Reserve University | Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer |
| US20040191782A1 (en) * | 2003-03-31 | 2004-09-30 | Yixin Wang | Colorectal cancer prognostics |
| US20070117164A1 (en) | 2003-04-08 | 2007-05-24 | Raskov Hans H | Method for detection of colorectal cancer in human samples |
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| US20050048494A1 (en) * | 2003-08-28 | 2005-03-03 | Yixin Wang | Colorectal cancer prognostics |
| CA2592504A1 (en) * | 2003-12-27 | 2005-07-14 | Aros Applied Biotechnology Aps | Classification of cancer |
-
2005
- 2005-12-23 NZ NZ544432A patent/NZ544432A/en unknown
-
2006
- 2006-12-22 ES ES06835771.4T patent/ES2525219T3/es active Active
- 2006-12-22 CA CA3015335A patent/CA3015335A1/en not_active Abandoned
- 2006-12-22 AU AU2006328023A patent/AU2006328023B2/en not_active Ceased
- 2006-12-22 KR KR1020137023872A patent/KR101530689B1/ko not_active Expired - Fee Related
- 2006-12-22 NZ NZ597363A patent/NZ597363A/xx unknown
- 2006-12-22 KR KR1020147036584A patent/KR101579934B1/ko not_active Expired - Fee Related
- 2006-12-22 ES ES11172410.0T patent/ES2484702T3/es active Active
- 2006-12-22 ES ES11172587.5T patent/ES2536233T3/es active Active
- 2006-12-22 EP EP11172410.0A patent/EP2371972B1/en not_active Not-in-force
- 2006-12-22 KR KR1020087018020A patent/KR101562644B1/ko not_active Expired - Fee Related
- 2006-12-22 WO PCT/NZ2006/000343 patent/WO2007073220A1/en not_active Ceased
- 2006-12-22 EP EP11172587.5A patent/EP2392678B1/en not_active Not-in-force
- 2006-12-22 NZ NZ586616A patent/NZ586616A/en unknown
- 2006-12-22 JP JP2008547140A patent/JP5632581B2/ja not_active Expired - Fee Related
- 2006-12-22 CN CN2006800529023A patent/CN101389957B/zh not_active Expired - Fee Related
- 2006-12-22 CA CA2640352A patent/CA2640352C/en not_active Expired - Fee Related
- 2006-12-22 EP EP06835771.4A patent/EP1977237B1/en not_active Not-in-force
-
2008
- 2008-06-20 US US12/214,782 patent/US10422005B2/en not_active Expired - Fee Related
-
2014
- 2014-05-19 JP JP2014103714A patent/JP6218141B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-21 US US14/860,024 patent/US20160068916A1/en not_active Abandoned
- 2015-12-28 JP JP2015257292A patent/JP6058780B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-27 US US16/552,737 patent/US11180815B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6058780B2 (ja) | 結腸直腸癌の予後予測 | |
| JP6824923B2 (ja) | 胃腸癌での増殖の徴候及び予後 | |
| JP6404304B2 (ja) | メラノーマ癌の予後予測 | |
| NZ555353A (en) | TNF antagonists | |
| HK1145342B (en) | Prognosis prediction for melanoma cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091221 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120514 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120813 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120822 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20121114 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121217 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130315 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130325 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130617 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140519 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140620 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140725 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140910 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141010 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5632581 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |